For patients with stage I/II NK/T-cell lymphoma, the sequence of radiotherapy and chemotherapy is controversial. Some studies demonstrated the advantage of upfront radiotherapy. Therefore, we designed this single-arm phase II study to evaluate the efficacy and safety of radiotherapy followed by adjuvant chemotherapy with DICE regimen plus peg-asparaginase which was proved to be effective in NK/T-cell lymphoma.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age range 14-70 years old
Histological confirmed, previously untreated stage I/II NK/T cell lymphoma in the upper-aerodigestive tract
ECOG performance status 0-1
Life expectancy of more than 3 months
Without prior history of pancreatitis
Adequate bone marrow and organ functions
You may not be if
Low risk population (Definition: stage I without local invasion, B symptoms and high LDH level)
Pregnant or lactating women
With contraindication of steroid including uncontrolled diabetes
Serious uncontrolled diseases and intercurrent infection
History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix